Related Experiment Videos
[Prolonged apnea after suxamethonium administration during staphylococcal toxic shock]
Y Blanloeil1, O Delaroche, B Tequi
1Service d'anesthésie et de réanimation chirurgicale, hôpital G- et R-Laennec, France.
Annales Francaises D'Anesthesie Et De Reanimation
|January 1, 1996
Summary
Toxic shock syndrome prolonged apnea after suxamethonium administration due to genetic plasma cholinesterase deficiency. This deficiency was exacerbated by toxic shock syndrome, necessitating avoidance of suxamethonium in such cases.
Area of Science:
- Anesthesiology
- Pharmacology
- Toxicology
Background:
- Toxic shock syndrome (TSS) is a severe, life-threatening condition.
- Suxamethonium is a muscle relaxant commonly used in anesthesia.
- Genetic variations in plasma cholinesterase can affect drug metabolism.
Observation:
- A patient undergoing femoral nail removal developed prolonged apnea after suxamethonium administration.
- The patient experienced two episodes of extended apnea following anesthesia, with the second episode being significantly longer.
- Plasma cholinesterase activity and dibucaine/fluorure numbers indicated a genetic deficiency.
Findings:
- The prolonged apnea was attributed to a genetic plasma cholinesterase deficiency, exacerbated by toxic shock syndrome.
- Toxic shock syndrome and suspected hepatic insufficiency likely contributed to decreased plasma cholinesterase levels.
- The patient's dibucaine and fluorure numbers confirmed a pseudocholinesterase deficiency.
Implications:
- Suxamethonium should be used with extreme caution or avoided in patients with toxic shock syndrome.
- Anesthesia protocols may need adjustment for patients with known or suspected pseudocholinesterase deficiencies, especially in critical conditions.
- Understanding drug metabolism in the context of severe illness is crucial for patient safety.